Table 4.

Numbers-needed-to-treat of SGLT-2 CVOTs renal outcome – stratified for eGFR

	eGFR ≥90 mL/min/1.73 m2	eGFR 60 to <90 mL/min/1.73 m2	eGFR <60 mL/min/1.73 m2		Renal composite
					eGFR ≥90 mL/min/1.73 m2	eGFR 60 to <90 mL/min/1.73 m2	eGFR <60 mL/min/1.73 m2
EMPA-REG OUTCOME	1,529 (21.9%)	3,638 (52.2%)	1,801 (25.8%)	HR	0.21 (0.09–0.53)	0.61 (0.37–1.03)	0.66 (0.41–1.07)
				ER	NA	NA	NA
				NNT	NA	NA	NA
CANVAS Program	2,039 (20.1%)	5,625 (55.5%)	2,476 (24.4%)	HR	0.44 (0.25–0.78)	0.58 (0.41–0.84)	0.74 (0.48–1.15)
				ER	3.8 vs 8.1	4.6 vs 7.4	11.4 vs 15.1
				NNT	48	74	57
DECLARE-TIMI 58	8,162 (47.6%)	7,732 (45.1%)	1,265 (7.4%)	HR	0.50 (0.34–0.73)	0.54 (0.40–0.73)	0.60 (0.35–1.02)
				ER	2.5 vs 4.9	4.2 vs 7.8	8.9 vs 15.2
				NNT	156	57	34
ALL CVOTS	11,730 (34.2%)	16,995 (49.6%)	5,542 (16.2%)	HR	0.44 (0.32–0.59)	0.56 (0.46–0.70)	0.67 (0.51–0.89)

Hazard ratios and event rates derive from Zelniker et al, 2018 (58). Abbreviations: SGLT-2 sodium glucose cotransporter-2, HF heart failure, 3p MACE 3-point composite of major adverse events, eCVD participants with established cardiovascular disease, RF participants with multiple risk factors, HR hazard ratio, ER Events per 1000 patient-years in treatment versus placebo group, vs versus, NA not available / not applicable. NNT number-needed-to-treat. NNTs are calculated by 1 / (1-EXP(-event rate with SGLT2 inhibition / 1000 [number of patient years] * 5 [time for NNT] ) - (1-EXP(-event rate with placebo / 1000 [number of patient years] * 5 [time for NNT]))) For EMPA-REG OUTCOME the renal composite is defined as doubling of serum creatinine, initiation of renal replacement therapy, or renal death. In the CANVAS Program, sustained 40% reduction in eGFR (MDRD), the need for renal-replacement therapy, or renal death was used. In DECLARE-TIMI 58, sustained 40% reduction in the eGFR (CKD-EPI), end-stage renal disease, or renal death was used.